Previous 10 | Next 10 |
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023 PR Newswire Immunological data from recently completed Phase 1b trial will be presented on April 16 th PLYMOUTH MEET...
2023-04-04 15:10:40 ET Shares of Inovio Pharmaceuticals (NASDAQ: INO) were down more than 10% on Tuesday afternoon, falling to a 52-week low of $0.07036 a share at one point. The biotechnology company specializes in developing DNA medicines to treat people with human papillomavi...
2023-04-04 07:37:12 ET Summary With its shares at historic lows, whether Inovio stock is a buying opportunity or a falling knife is a tough nut to crack. It has had a series of disappointing readouts that are putting it in serious data crunching mode. Lead therapy switcheroo i...
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa. , April 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV...
2023-03-13 15:03:02 ET Inovio Pharmaceuticals, Inc. (INO) Oppenheimer 33rd Annual Healthcare Conference Call March 13, 2023 10:40 ET Company Participants Jacqueline Shea - President and Chief Executive Officer Conference Call Participants Hartaj Singh - Oppen...
INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire PLYMOUTH MEETING, Pa. , March 3, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect...
Inovio Pharmaceuticals ( NASDAQ: INO ) stock rose ~7% on Thursday after the company reported results from a phase 3 trial and provided other clinical updates with its Q4 results. Phase 3 trial for VGX-3100 in Cervical HSIL: The study, dubbed REVEAL2, evaluating VG...
Inovio Pharmaceuticals, Inc. (INO) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Thomas Hong - Manager-Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies...
Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q4 2022 Earnings Call Mar 01, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript
Inovio Pharmaceuticals press release ( NASDAQ: INO ): FY GAAP EPS of -$1.17 misses by $0.06 . Revenue of $10.26M (+479.7% Y/Y) misses by $0.29M . For further details see: Inovio Pharmaceuticals GAAP EPS of -$1.17 misses by $0.06, revenue of $10.26M misses by $0.29M
News, Short Squeeze, Breakout and More Instantly...
Inovio Pharmaceuticals Inc. Company Name:
INO Stock Symbol:
NASDAQ Market:
Inovio Pharmaceuticals Inc. Website:
5G leader welcomes new Chief Product Officer, Senior Vice President Sales/Service Providers and Head of Operations Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises, and SMBs, today announced...
2024-07-16 13:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Inseego Corp. (Nasdaq: INSG), a technology leader in 5G mobile and fixed wireless solutions for mobile network operators, Fortune 500 enterprises and SMBs, today announced that the company will release its financial results for the second quarter of 2024, ended June 30, 2024, after the financial ...